American Heart Journal
Volume 147, Issue 2 , Pages 228-237 , February 2004

Conflict of interest

  • David R Holmes Jr, MD

      Affiliations

    • Mayo Clinic, Rochester, Minn, USA
    • Corresponding Author InformationReprint requests: David R. Holmes, Jr, MD, Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, 200 First Street NW, Rochester, MN 55905, USA
    • ,
  • Brian G Firth, MD, PhD

      Affiliations

    • Cordis Corporation, Warren, NJ, USA
    • ,
  • Astrid James, MBBS

      Affiliations

    • The Lancet, London, United Kingdom
    • ,
  • Ron Winslow, BA

      Affiliations

    • The Wall Street Journal, New York, NY, USA
    • ,
  • Patricia K Hodgson, BA

      Affiliations

    • Duke Clinical Research Institute, Durham, NC, USA
    • ,
  • Gail L Gamble, MD

      Affiliations

    • Mayo Clinic, Rochester, Minn, USA
    • ,
  • Richard L Popp, MD

      Affiliations

    • Stanford University, Stanford, Calif, USA
    • ,
  • Robert A Harrington, MD

      Affiliations

    • Duke Clinical Research Institute, Durham, NC, USA

References 

  1. Thompson DF. Understanding financial conflicts of interest. N Engl J Med. 1993;329:573–576
  2. Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research (a systematic review). JAMA. 2003;289:454–465
  3. Task Force on Financial Conflicts of Interest in Clinical Research. Protecting subjects, preserving trust, promoting progress: policy and guidelines for the oversight of individual financial interests in human subjects research. Washington, DC: Association of American Medical Colleges; December 2001. Available at: www.aamc.org
  4. Task Force on Financial Conflicts of Interest in Clinical Research. Protecting subjects, preserving trust, promoting progress II: principles and recommendations for oversight of an institution's financial interests in human subjects research. Washington, DC: Association of American Medical Colleges; October 2002. Available at: www.aamc.org
  5. Council on Ethical and Judicial Affairs. Conflicts of interest in biomedical research. Chicago: American Medical Association; June 1999. Available at: www.ama-assn.org
  6. PhRMA code on interactions with healthcare professionals. Washington, DC: Pharmaceutical Research and Manufacturers of America; July 2002. Available at: www.phrma.org/issues
  7. McCrary SV, Anderson CB, Jakovljevic J, et al.  A national survey of policies on disclosure of conflicts of interest in biomedical research. N Engl J Med. 2000;343:1621–1626
  8. Lo B, Wolf LE, Berkeley A. Conflict-of-interest policies for investigators in clinical trials. N Engl J Med. 2000;343:1616–1620
  9. Schulman KA, Seils DM, Timbie JW, et al.  A national survey of provisions in clinical-trial agreements between medical schools and industry sponsors. N Engl J Med. 2002;347:1335–1341
  10. Stolberg SG. The biotech death of Jesse Gelsinger. New York Times Magazine. November 29, 1999:137–43. Available at: http://www.uvm.edu/∼biology/Classes/012/Jess.pdf
  11. NIH Grants Policy Statement. Financial conflict of interest. Available at: http://grants.nih.gov/grants/policy/nihgps_2001/part_iia_1.htm#_Toc504811782
  12. Food and Drug Administration Modernization Act of 1997. Available at: www.nih.gov/cdrh/modact97
  13. AdvaMed Board of Directors Unanimously Approves Code of Ethics for Interactions with Health Care Professionals. Available at: http://www.advamed.org/publicdocs/PR-168.htm
  14. Journalism Credibility Project. Reston (Va): American Society of Newspaper Editors; 1998. Available at: www.asne.org
  15. Fletcher RH, Fletcher SW. Pharmaceutical advertisements in medical journals. Ann Intern Med. 1992;116:951–952
  16. Kassirer JP. Editorial independence. N Engl J Med. 1999;340:1671–1672
  17. Silverstein FE, Faich G, Goldstein JL, et al.  Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis (the CLASS study: a randomized controlled trial). JAMA. 2000;284:1247–1255
  18. Hrachovec JB, Mora M. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. JAMA. 2001;286:2398
  19. Dong BJ, Hauck WW, Gambertoglio JG, et al.  Bioequivalence of generic and brand-name levothyroxine products in the treatment of hypothyroidism. JAMA. 1997;277:1205–1213
  20. Nathan DG, Weatherall DJ. Academia and industry (lessons from the unfortunate events in Toronto). Lancet. 1999;353:771–772
  21. International Committee of Medical Journal Editors. Uniform requirements for manuscripts submitted to biomedical journals. 2001. Available at: www.icmje.org
  22. Davidoff F, DeAngelis CD, Drazen JM, et al.  Sponsorship, authorship and accountability. Lancet. 2001;358:854–856
  23. Kassirer JP. Goodbye, for now. N Engl J Med. 1999;341:686–687
  24. Horton R. The sacking of JAMA. Lancet. 1999;353:252–253
  25. Standards of Ethical Conduct for Employees of the Executive Branch (5 Code of Federal Regulations, Part 2635). Available at: http://www.nsf.gov/home/pubinfo/coi/5cfr2635.htm and www.nih.gov
  26. Office of the Federal Register, National Archives and Records Administration, United States Government Printing Office. 42 Code of Federal Regulations, Part 50.604 and 45 Code of Federal Regulations, Part 94.4. Available at: http://www.access.gpo.gov/nara/cfr/

PII: S0002-8703(03)00833-0

doi: 10.1016/j.ahj.2003.12.001

American Heart Journal
Volume 147, Issue 2 , Pages 228-237 , February 2004

Article Tools

* Image Usage & Resolution